This interview features: Jean Luo, Vice President and General Manager, Purification and Pharma Analytics, Thermo Fisher Scientific Jean Luo shared some of Thermo Fisher’s innovative new purification and PCR products at the BioProcess International West 2023 conference. She also discussed some efforts Thermo Fisher has taken to reduce lead times for supplies, as well as help customers avoid regulatory delays.
Details remain scarce but Gracell Biotech inked a cell therapy development deal days before Pfizer confirmed it is set to buy Seagen. Shanghai cell and gene therapy company Gracell announced in a press release that it had entered an unusual, non-exclusive global deal with Seattle’s Seagen to conduct pre-clinical research on Seagen’s cell therapy products and acquire (non-exclusive) rights to five of Seagen’s cell therapies. The press release was dated March 8, 2023, which was before Seagen announced on Monday,…
Cellipont Bioservices will use the strategic debt facility investment from healthcare investment firm OrbiMed to finish its Texas plant. Cellipont Bioservices, previously known as Performance Cell Manufacturing, after being acquired by private equity firm Great Point Partners in January 2022 said the investment from OrbiMed will fully finance its cell therapy facility in The Woodlands, near Hosuton, Texas. The financial details of the investment have not been disclosed. However, the San Diego-based contract development and manufacturing organization (CDMO) announced its…
The global economic landscape and supply chain challenges have led Boehringer Ingelheim to reexamine plans to construct a biologics plant in Bruck an der Leitha, Austria. Fresh off the back of opening its €700 million ($761 million) biomanufacturing plant in Vienna, Boehringer Ingelheim revealed plans to invest a further €1.2 billion to build another facility in Austria. The announcement made in German in April 2022 signaled the BioNEX facility would provide additional capacity for biologics production through construction of up…
There are solutions available to alleviate talent shortages in the biopharma space but the issues cannot be solved quickly. There is a general consensus among professionals that the amount of talent coming through is not reflective of the huge investment in capacity being seen across the Life Sciences industry. The lack of qualified staff in the space is well documented, with the cell and gene therapy sector particularly affected. Solutions to minimize the talent gap have been provided by different players in…